He Junli's Form 4 filing
Harvard Apparatus Regenerative Technology, Inc. (HRGN) · filed Sep 25, 2026
- Accession no.
- 0001437749-26-031181
- Filed
- Sep 25, 2026, 10:51 AM ET
- Trade date
- Sep 11-15, 2026
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $394.5K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| He JunliCIK 0001728598 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | CConversionAcquired | +683,725 | $1.05 | +$717,911.25 | 964,300 | Direct | |
| Sep 11, 2026 | Common Stock | PPurchaseAcquired | +361,905 | $1.05 | +$380,000.25 | 1,326,205 | Direct | |
| Sep 15, 2026 | Common Stock | PPurchaseAcquired | +6,725 | $2.15F3 | +$14,458.75 | 1,332,930 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 15, 2026 to September 23, 2026. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
Each bridge note provided that, upon a qualified equity financing of the Issuer, the Reporting Person could elect to convert the full balance of the note (principal and accrued interest) into the equity securities sold in such financing at the per-unit price paid by the purchasers in the financing. Because the conversion price was not fixed until the closing of the Private Placement, the notes were not derivative securities prior to that date pursuant to Rule 16a-1(c)(6). The conversion price became fixed at $1.05 per share upon the closing of the Private Placement on September 11, 2026, and the Reporting Person converted the full balance of each note on that date.
Referenced by the price of 3 transactions in Table II.